NeuroPace to Present at the Leerink Global Healthcare Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink 2026 Global Healthcare Conference at 8:40am PT on Wednesday, March 11, 2026, in Miami, FL. Management will also host investor meetings during the conference.

The presentation will be accessible via live webcast here. A webcast replay will be available for thirty days following the presentation in the Events & Presentations section of NeuroPace’s Investor website at https://investors.neuropace.com.

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.70
+0.00 (0.00%)
AAPL  263.40
+0.00 (0.00%)
AMD  278.26
+0.00 (0.00%)
BAC  53.51
+0.00 (0.00%)
GOOG  332.77
+0.00 (0.00%)
META  676.87
+0.00 (0.00%)
MSFT  420.26
+0.00 (0.00%)
NVDA  198.35
+0.00 (0.00%)
ORCL  178.34
+0.00 (0.00%)
TSLA  388.90
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.